AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

July 8, 2021 GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 8, 2021--

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Thursday, July 29. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/ces2j4at. A webcast replay will be available following conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

ADVERTISEMENT

The conference call can be accessed as follows:

 

 

U.S./Canada participant dial-in number (toll-free):

(855) 541-0980

International participant dial-in number:

(970) 315-0440

Conference I.D.:

1997209

About Veracyte

ADVERTISEMENT

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com:https://www.businesswire.com/news/home/20210708005868/en/

CONTACT: Investor and Media Contact:Tracy Morris

Vice President of Corporate Communications

& Investor Relations

650-380-4413

tracy.morris@veracyte.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SURGERY BIOTECHNOLOGY RADIOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY

SOURCE: Veracyte, Inc.

Copyright Business Wire 2021.

PUB: 07/08/2021 04:05 PM/DISC: 07/08/2021 04:06 PM

http://www.businesswire.com/news/home/20210708005868/en